WASHINGTON--(BUSINESS WIRE)--A universal flu vaccine candidate that could end the need for annual flu shots and provide protection against seasonal and pandemic flu strains was well tolerated and immunogenic in a Phase I study that was presented at the joint 48th ICAAC/46th IDSA annual meetings here today.
